Automated amplification-free digital RNA detection platform for rapid and sensitive SARS-CoV-2 diagnosis

In the ongoing COVID-19 pandemic, rapid and sensitive diagnosis of viral infection is a critical deterrent to the spread of SARS-CoV-2. To this end, we developed an automated amplification-free digital RNA detection platform using CRISPR-Cas13a and microchamber device (opn-SATORI), which automatical...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinoda, Hajime, Iida, Tatsuya, Makino, Asami, Yoshimura, Mami, Ishikawa, Junichiro, Ando, Jun, Murai, Kazue, Sugiyama, Katsumi, Muramoto, Yukiko, Nakano, Masahiro, Kiga, Kotaro, Cui, Longzhu, Nureki, Osamu, Takeuchi, Hiroaki, Noda, Takeshi, Nishimasu, Hiroshi, Watanabe, Rikiya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132978/
https://www.ncbi.nlm.nih.gov/pubmed/35614128
http://dx.doi.org/10.1038/s42003-022-03433-6
Descripción
Sumario:In the ongoing COVID-19 pandemic, rapid and sensitive diagnosis of viral infection is a critical deterrent to the spread of SARS-CoV-2. To this end, we developed an automated amplification-free digital RNA detection platform using CRISPR-Cas13a and microchamber device (opn-SATORI), which automatically completes a detection process from sample mixing to RNA quantification in clinical specimens within ~9 min. Using the optimal Cas13a enzyme and magnetic beads technology, opn-SATORI detected SARS-CoV-2 genomic RNA with a LoD of < 6.5 aM (3.9 copies μL(−1)), comparable to RT-qPCR. Additionally, opn-SATORI discriminated between SARS-CoV-2 variants of concern, including alpha, delta, and omicron, with 98% accuracy. Thus, opn-SATORI can serve as a rapid and convenient diagnostic platform for identifying several types of viral infections.

Ejemplares similares